Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of Alzheimer's disease
Disclosed are transgenic animals and transfected cell lines expressing a protein associated with Alzheimer's Disease, neuroectodermal tumors, malignant astrocytomas, and glioblastomas. Also disclosed is the use of such transgenic animals and transfected cell lines to screen potential drug candidates for treating or preventing Alzheimer's disease, neuroectodermal tumors, malignant astrocytomas, and glioblastomas. The invention also relates to new antisense oligonucleotides, ribozymes, triplex forming DNA and external guide sequences that can be used to treat or prevent Alzheimer's disease, neuroectodermal tumors, malignant astrocytomas, and glioblastomas.
1. An antisense oligonucleotide which is complementary to an NTP mRNA sequence, wherein said antisense oligonucleotide is selected from the group consisting of SEQ ID NO:9, SEQ ID NO:10 and SEQ ID NO:11.
2. The antisense oligonucleotide of claim 1 , which is deoxyribonucleic acid.
3. The antisense oligonucleotide of claim 1 , which is deoxyribonucleic acid phosphorothioate.
4. The antisense oligonucleotide of claim 1 , which is a derivative of a deoxyribonucleic acid or a deoxyribonucleic acid phosphorothioate.
5. A pharmaceutical composition comprising the antisense oligonucleotide of claim 1 and a pharmaceutically acceptable carrier.
6. A ribonucleotide external guide nucleic acid molecule comprising a 10-mer nucleotide sequence fused to a 3′NCCA nucleotide sequence, wherein N is a purine, wherein said ribonucleotide external guide nucleic acid molecule is selected from the group consisting of SEQ ID NO:12, SEQ ID NO:13 and SEQ ID NO:14.
7. A pharmaceutical composition comprising the ribonucleotide of claim 6 and a pharmaceutically acceptable carrier.
8. An antisense oligonucleotide, which is a 15 to 40 mer and is complementary to an NTP mRNA sequence corresponding to a region within nucleotides 150–1139 of SEQ ID NO:1, wherein said region includes one or more nucleotides selected from the group consisting of nucleotides 150, 194–195, 240–241, 243, 244, 255–256, 266–267, 269–271, 276, 279–280, 293–295, 338–340, 411, 459, 532–533, 591, 633–644, 795–797, 828, 853–854, 876–877, 883, 884–885, 898, 976, 979–980, 999, 1037, 1043–1044, 1092–1096, 1099, and 1116–1119 of SEQ ID NO:1.
9. The antisense oligonucleotide of claim 8 , which is deoxyribonucleic acid.
10. The anti sense oligonucleotide of claim 8 , which is deoxyribonucleic acid phosphorothioate.
11. The antisense oligonucleotide of claim 8 , which is a derivative of a deoxyribonucleic acid or a deoxyribonucleic acid phosphorothioate.
12. A pharmaceutical composition comprising the antisense oligonucleotide of claim 8 and a pharmaceutically acceptable carrier.